Spinal and bulbar muscular atrophy: From molecular pathogenesis to pharmacological intervention targeting skeletal muscle.
Marchioretti C, Andreotti R, Zuccaro E, Lieberman AP, Basso M, Pennuto M.
Curr Opin Pharmacol. 2023 Aug;71:102394. doi: 10.1016/j.coph.2023.102394. Epub 2023 Jul 16.
Kennedy's disease (spinal and bulbar muscular atrophy): a clinically oriented review of a rare disease.
Breza M, Koutsis G.
J Neurol. 2019 Mar;266(3):565-573. doi: 10.1007/s00415-018-8968-7. Epub 2018 Jul 13.
Spinal and bulbar muscular atrophy.
Lieberman AP.
Handb Clin Neurol. 2018;148:625-632. doi: 10.1016/B978-0-444-64076-5.00040-5.
Spinal and Bulbar Muscular Atrophy.
La Spada A.
1999 Feb 26 [updated 2026 Jan 8]. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2026.
Metabolic alterations in spinal and bulbar muscular atrophy.
Francini-Pesenti F, Vitturi N, Tresso S, Sorarù G.
Rev Neurol (Paris). 2020 Dec;176(10):780-787. doi: 10.1016/j.neurol.2020.03.020. Epub 2020 Jul 4.
Disease mechanism, biomarker and therapeutics for spinal and bulbar muscular atrophy (SBMA).
Hashizume A, Fischbeck KH, Pennuto M, Fratta P, Katsuno M.
J Neurol Neurosurg Psychiatry. 2020 Oct;91(10):1085-1091. doi: 10.1136/jnnp-2020-322949.
Spinal and Bulbar Muscular Atrophy Overview.
Fischbeck KH.
J Mol Neurosci. 2016 Mar;58(3):317-20. doi: 10.1007/s12031-015-0674-7. Epub 2015 Nov 7.
The role of ubiquitination in spinal and bulbar muscular atrophy.
Sengupta M, Pluciennik A, Merry DE.
Front Mol Neurosci. 2022 Oct 6;15:1020143. doi: 10.3389/fnmol.2022.1020143. eCollection 2022.
Spinal and bulbar muscular atrophy: pathogenesis and clinical management.
Grunseich C, Rinaldi C, Fischbeck KH.
Oral Dis. 2014 Jan;20(1):6-9. doi: 10.1111/odi.12121. Epub 2013 May 9.
Spinal and Bulbar Muscular Atrophy.
Grunseich C, Fischbeck KH.
Neurol Clin. 2015 Nov;33(4):847-54. doi: 10.1016/j.ncl.2015.07.002. Epub 2015 Sep 8.
